Litcius/Paper detail

710P Neoadjuvant tislelizumab for resectable recurrent hepatocellular carcinoma: A non-randomized control, phase II trial (TALENT)

S. Chen, Y. Wang, Wenxuan Xie, S. Shen, Sui Peng, Ming Kuang

2022Annals of Oncology12 citationsDOI

Topics & Concepts

MedicineHepatocellular carcinomaOncologyRandomized controlled trialNeoadjuvant therapyInternal medicineCancerBreast cancerHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathologyPancreatic and Hepatic Oncology Research